BACKGROUND Gastroesophageal reflux disease(GERD)has a high prevalence worldwide,and its incidence is increasing annually.Modified Xiaochaihu Decoction(MXD)could relieve the symptoms of GERD,but the effects of MXD on G...BACKGROUND Gastroesophageal reflux disease(GERD)has a high prevalence worldwide,and its incidence is increasing annually.Modified Xiaochaihu Decoction(MXD)could relieve the symptoms of GERD,but the effects of MXD on GERD manifestations and relapse prevention need to be further explained.Therefore,we performed a prospective,double-blind,and double-simulation study.AIM To verify the efficacy of MXD for GERD and its effect on esophageal motility.METHODS Using randomization,double-blinding,and a simulation design,288 participants with GERD were randomized to the treatment group and control group and received herbs(MXD)plus omeprazole simulation and omeprazole plus herbs simulation,respectively,for 4 wk.The GERD-Q scale score and esophageal manometry were measured at baseline,after treatment,and at 1 mo and 3 mo follow-up visits when medication was complete to evaluate recurrence indicators.RESULTS The GERD-Q scale score in both groups decreased significantly compared to those before treatment(P<0.01).However,no significant difference was observed between the two groups(P>0.05).Esophageal manometry showed that participants with lower esophageal sphincter pressure reduction and the proportion of ineffective swallowing(more than 50%)improved in both groups from baseline(P<0.01),especially in the treatment group(P<0.05).The percentage of small intermittent contractions,large intermittent contractions,and increased pre-phase contractions in the treatment group significantly improved compared with baseline(P<0.05)but did not improve in the control group(P>0.05).There was no significant difference between the groups after treatment(P>0.05).The percentage of weak esophageal contractility(distal contractile integral<450 mmHg·s·cm),improved in both groups(P<0.01),but no significant difference was observed between the groups after treatment(P>0.05).The relapse rate in the treatment group was lower than that in the control group at the 1 mo(P<0.01)and 3 mo follow-up(P<0.05).CONCLUSION MXD has a similar therapeutic effect to omeprazole in mild-to-moderate GERD.The therapeutic effect may be related to increased pressure in the lower esophageal sphincter and reduced ineffective swallowing.展开更多
APLASTIC anemia (AA) is a bone marrow failure disease caused by abnormal activation of T lymphocytes, resulting in the apoptosis of he- matopoietic cells and bone marrow failure.
To the Editor:The t(9;22)(q34;q 11) (Philadelphia chromosome [Ph]) balanced translocation results in fusion of the BCR gene at 22q11 with cytoplasmic tyrosine kinase gene ABL1 and plays an essential role in leu...To the Editor:The t(9;22)(q34;q 11) (Philadelphia chromosome [Ph]) balanced translocation results in fusion of the BCR gene at 22q11 with cytoplasmic tyrosine kinase gene ABL1 and plays an essential role in leukemic transformation.The Ph is an infrequent finding in de novo acute myeloid leukemia (AML),approximately 0.5-3% of newly diagnosed patients. The World Health Organization (WHO) recently released a revised version of the Classification of Hematopoietic and Lymphoid Malignancies,a new provisional category of AM L with BCR-ABL1 was added to recognize these rare Ph AML cases that could benefit from tyrosine-kinase inhibitor (TKI) therapy. It is required to enlarge the sample size and research the molecular or genomic features to increase the argument in favor ofPh AML as a real entity.展开更多
基金Supported by Capital Characteristic Study of Clinical Application,Beijing Municipal Science&Technology Commission,No.Z141107002514176Capital Health Development Research Project,No.2018-2-2231.
文摘BACKGROUND Gastroesophageal reflux disease(GERD)has a high prevalence worldwide,and its incidence is increasing annually.Modified Xiaochaihu Decoction(MXD)could relieve the symptoms of GERD,but the effects of MXD on GERD manifestations and relapse prevention need to be further explained.Therefore,we performed a prospective,double-blind,and double-simulation study.AIM To verify the efficacy of MXD for GERD and its effect on esophageal motility.METHODS Using randomization,double-blinding,and a simulation design,288 participants with GERD were randomized to the treatment group and control group and received herbs(MXD)plus omeprazole simulation and omeprazole plus herbs simulation,respectively,for 4 wk.The GERD-Q scale score and esophageal manometry were measured at baseline,after treatment,and at 1 mo and 3 mo follow-up visits when medication was complete to evaluate recurrence indicators.RESULTS The GERD-Q scale score in both groups decreased significantly compared to those before treatment(P<0.01).However,no significant difference was observed between the two groups(P>0.05).Esophageal manometry showed that participants with lower esophageal sphincter pressure reduction and the proportion of ineffective swallowing(more than 50%)improved in both groups from baseline(P<0.01),especially in the treatment group(P<0.05).The percentage of small intermittent contractions,large intermittent contractions,and increased pre-phase contractions in the treatment group significantly improved compared with baseline(P<0.05)but did not improve in the control group(P>0.05).There was no significant difference between the groups after treatment(P>0.05).The percentage of weak esophageal contractility(distal contractile integral<450 mmHg·s·cm),improved in both groups(P<0.01),but no significant difference was observed between the groups after treatment(P>0.05).The relapse rate in the treatment group was lower than that in the control group at the 1 mo(P<0.01)and 3 mo follow-up(P<0.05).CONCLUSION MXD has a similar therapeutic effect to omeprazole in mild-to-moderate GERD.The therapeutic effect may be related to increased pressure in the lower esophageal sphincter and reduced ineffective swallowing.
基金Supported by Key Provincial Talents Program of Jiangsu(H201126)the Natural Science Fund for Colleges and Universities of Jiangsu Province (09KJB320015)+1 种基金Key Projects in the National Science & Technology Pillar Program (2008BAI61B02 and 2008ZX09312-026)the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
文摘APLASTIC anemia (AA) is a bone marrow failure disease caused by abnormal activation of T lymphocytes, resulting in the apoptosis of he- matopoietic cells and bone marrow failure.
基金This work was supported by grants from the National Natural Science funds (No. 81500103), Natural Science Foundation of Jiangsu Province (BK-20151230), and the high-level medical talents training project (No. 2016CZLJ027).
文摘To the Editor:The t(9;22)(q34;q 11) (Philadelphia chromosome [Ph]) balanced translocation results in fusion of the BCR gene at 22q11 with cytoplasmic tyrosine kinase gene ABL1 and plays an essential role in leukemic transformation.The Ph is an infrequent finding in de novo acute myeloid leukemia (AML),approximately 0.5-3% of newly diagnosed patients. The World Health Organization (WHO) recently released a revised version of the Classification of Hematopoietic and Lymphoid Malignancies,a new provisional category of AM L with BCR-ABL1 was added to recognize these rare Ph AML cases that could benefit from tyrosine-kinase inhibitor (TKI) therapy. It is required to enlarge the sample size and research the molecular or genomic features to increase the argument in favor ofPh AML as a real entity.